ABP Live
2024 · Expert Commentary
Navigating Legal Challenges in the Development of the Pharmaceutical Sector in India
Advocate Srijan Tiwari examines CDSCO regulatory enforcement, drug quality prosecutions, and strategic guidance for pharmaceutical corporations — published on ABP Live.
Read Original Article on ABP Live ↗About This Publication
This expert commentary was authored by Advocate Srijan Tiwari — Delhi's foremost drug and cosmetics litigation specialist — and published on ABP Live, one of India's leading digital news platforms with over 50 million monthly visitors. The article is directly relevant to Advocate Tiwari's core practice area.
The Legal Landscape of India's Pharma Sector
India's pharmaceutical industry — the world's third largest by volume — operates within one of the most complex regulatory environments globally. The Drugs and Cosmetics Act, 1940, administered jointly by the Central Drugs Standard Control Organisation (CDSCO) and State Drug Authorities, creates a layered compliance obligation that every pharmaceutical company must navigate carefully.
Advocate Srijan Tiwari's ABP Live article identifies the primary legal challenges pharmaceutical corporations face today — and the strategic approaches that have proven effective in his 14+ years of exclusive drug law litigation practice at the Delhi High Court.
Major Legal Challenges for Pharma Corporations
NSQ (Not of Standard Quality) Prosecutions
When a drug or cosmetic product fails government quality testing, the company faces criminal prosecution under Sections 27-28 of the Drugs and Cosmetics Act. NSQ cases are the most common form of drug law prosecution — and the most aggressively defended by Advocate Tiwari's practice.
CDSCO Regulatory Enforcement Actions
The Central Drugs Standard Control Organisation has dramatically increased enforcement activity — including import alerts, product recalls, and market withdrawal orders. These actions can be challenged through administrative proceedings and writ petitions at Delhi High Court.
Drug Licence Suspensions and Cancellations
State Drug Authorities have the power to suspend or cancel manufacturing, sales, and wholesale licences. Many such actions are taken without adequate opportunity to be heard — grounds for immediate legal challenge on natural justice principles.
Show Cause Notices and Prosecution Risk
Show cause notices from drug authorities are often the precursor to prosecution. Strategic engagement at this stage — with proper legal representation — can prevent the matter from escalating to criminal proceedings.
Strategic Guidance from the Article
Advocate Tiwari's article emphasises that the most effective approach to pharmaceutical legal challenges is proactive — not reactive. Companies that have robust internal compliance systems, maintain detailed records of manufacturing and testing protocols, and engage specialist legal counsel at the earliest sign of regulatory attention consistently achieve better outcomes.
For companies already facing prosecution or regulatory action, the article identifies key defences — including challenging the sampling procedure, questioning the government analyst's qualifications, and seeking CDL counter-analysis — strategies that have been successfully deployed in hundreds of NSQ cases at Delhi courts.
Facing a Pharmaceutical Legal Challenge?
Advocate Srijan Tiwari is available for confidential consultations on NSQ prosecutions, CDSCO enforcement actions, drug licence matters, and all pharmaceutical regulatory disputes at Delhi High Court.
Publication Details
Drug Law Resources